Clinical Trials Directory

We are doing this study to find out if radiation to the axillary (armpit) lymph nodes is equally effective and causes fewer side effects than surgical removal of the lymph nodes in patients with breast cancer.

We are doing this study to find out if avelumab is a safe and effective option for triple negative metastatic breast cancer when it is combined with different anti-cancer drugs.

We are doing this study to find out if an experimental drug called TL-895 (the study drug) is a safe and effective option for people with indolent systemic mastocytosis.

We are doing this study to find the most effective, safe dose of an experimental drug called iadademstat (the study drug). We want to know if the study drug is beneficial for people with R/R AML that have the FLT3 mutation when it is given in combination with gilteritinib.

We are doing this study to find out if 2 investigational drugs called aliocumab and cemiplimab (the study drugs) are a safe and effective option to treat NSCLC that has spread to other organs in the body and help patients live disease free for a longer period of time.

We are doing this research study to learn about the safety and effectiveness of alirocumab (a cholesterol-lowering drug) when it is combined with cemiplimab (an immunotherapy drug) and preoperative chemotherapy in patients with stage 1B-3A non-small cell lung cancer (NSCLC) who will undergo surgery. This study is important because it might potentially improve outcomes for you and other future patients.

We are doing this study to find the most effective, safe dose of an experimental drug called rilvegostomig (the study drug). We want to know how well the study drug works on its own and when it is used in combination with another anti-cancer drug called datopotamab deruxtecan (also called Dato-DXd). We will compare how well both of these regimens work versus the standard treatment for non-small cell lung cancer (NSCLC) that is ctDNA-positive.